VERTEX PHARMACEUTICALS INC / MA OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax of -$169.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2019-12-31 was -$72.00K.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2019-09-30 was $64.00K, a 71.43% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2019-06-30 was $451.00K, a 20.91% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2019-03-31 was $596.00K.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2020 was -$169.00K, a 116.27% decline from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2019 was $1.04M, a 1691.38% increase from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2018 was $58.00K, a 99.17% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2017 was $6.95M, a 60.02% decline from fiscal 2016.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | -$169.00K 10-K · filed 2021-02-11 | ||||
| 2019-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$8.00K derived: sum of 2 quarters · filed 2021-02-11 | $443.00K derived: sum of 3 quarters · filed 2021-02-11 | $1.04M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $64.00K 10-Q · filed 2019-10-31 | $515.00K derived: sum of 2 quarters · filed 2019-10-31 | $1.11M 10-Q · filed 2019-10-31 | $1.03M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $451.00K 10-Q · filed 2019-08-01 | $1.05M 10-Q · filed 2019-08-01 | $968.00K derived: sum of 3 quarters · filed 2021-02-11 | $1.19M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | $596.00K 10-Q · filed 2019-05-01 | $517.00K derived: sum of 2 quarters · filed 2021-02-11 | $741.00K derived: sum of 3 quarters · filed 2021-02-11 | $1.11M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | -$79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $145.00K derived: sum of 2 quarters · filed 2021-02-11 | $518.00K derived: sum of 3 quarters · filed 2021-02-11 | $58.00K 10-K · filed 2021-02-11 | |
| 2018-09-30 | $224.00K 10-Q · filed 2019-10-31 | $597.00K derived: sum of 2 quarters · filed 2019-10-31 | $137.00K 10-Q · filed 2019-10-31 | $14.88M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | $373.00K 10-Q · filed 2019-08-01 | -$87.00K 10-Q · filed 2019-08-01 | $14.65M derived: sum of 3 quarters · filed 2020-02-13 | $20.61M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | -$460.00K 10-Q · filed 2019-05-01 | $14.28M derived: sum of 2 quarters · filed 2020-02-13 | $20.24M derived: sum of 3 quarters · filed 2020-02-13 | $2.96M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2017-12-31 | $14.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $20.70M derived: sum of 2 quarters · filed 2020-02-13 | $3.42M derived: sum of 3 quarters · filed 2020-02-13 | $6.95M 10-K · filed 2020-02-13 | |
| 2017-09-30 | $5.96M 10-Q · filed 2018-10-25 | -$11.32M derived: sum of 2 quarters · filed 2018-10-25 | -$7.79M 10-Q · filed 2018-10-25 | $9.51M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-06-30 | -$17.28M 10-Q · filed 2018-07-26 | -$13.75M 10-Q · filed 2018-07-26 | $3.54M derived: sum of 3 quarters · filed 2019-02-13 | $3.45M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-03-31 | $3.53M 10-Q · filed 2018-04-27 | $20.82M derived: sum of 2 quarters · filed 2019-02-13 | $20.73M derived: sum of 3 quarters · filed 2019-02-13 | $20.70M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2016-12-31 | $17.29M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $17.20M derived: sum of 2 quarters · filed 2019-02-13 | $17.17M derived: sum of 3 quarters · filed 2019-02-13 | $17.39M 10-K · filed 2019-02-13 | |
| 2016-09-30 | -$96.00K 10-Q · filed 2017-10-30 | -$125.00K derived: sum of 2 quarters · filed 2017-10-30 | $104.00K 10-Q · filed 2017-10-30 | $167.00K derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-06-30 | -$29.00K 10-Q · filed 2017-07-28 | $200.00K 10-Q · filed 2017-07-28 | $263.00K derived: sum of 3 quarters · filed 2018-02-15 | $319.00K derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-03-31 | $229.00K 10-Q · filed 2017-04-28 | $292.00K derived: sum of 2 quarters · filed 2018-02-15 | $348.00K derived: sum of 3 quarters · filed 2018-02-15 | $302.00K derived: sum of 4 quarters · filed 2018-02-15 | |
| 2015-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $119.00K derived: sum of 2 quarters · filed 2018-02-15 | $73.00K derived: sum of 3 quarters · filed 2018-02-15 | $249.00K 10-K · filed 2018-02-15 | |
| 2015-09-30 | $56.00K 10-Q · filed 2016-10-31 | $10.00K derived: sum of 2 quarters · filed 2016-10-31 | $186.00K 10-Q · filed 2016-10-31 | -$4.00K derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-06-30 | -$46.00K 10-Q · filed 2016-08-01 | $130.00K 10-Q · filed 2016-08-01 | -$60.00K derived: sum of 3 quarters · filed 2017-02-23 | -$90.00K derived: sum of 4 quarters · filed 2017-02-23 | |
| 2015-03-31 | $176.00K 10-Q · filed 2016-05-03 | -$14.00K derived: sum of 2 quarters · filed 2017-02-23 | -$44.00K derived: sum of 3 quarters · filed 2017-02-23 | $38.00K derived: sum of 4 quarters · filed 2017-02-23 | |
| 2014-12-31 | -$190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$220.00K derived: sum of 2 quarters · filed 2017-02-23 | -$138.00K derived: sum of 3 quarters · filed 2017-02-23 | -$165.00K 10-K · filed 2017-02-23 | |
| 2014-09-30 | -$30.00K 10-Q · filed 2015-10-30 | $52.00K derived: sum of 2 quarters · filed 2015-10-30 | $25.00K 10-Q · filed 2015-10-30 | -$136.00K derived: sum of 4 quarters · filed 2016-02-16 | |
| 2014-06-30 | $82.00K 10-Q · filed 2015-08-04 | $55.00K 10-Q · filed 2015-08-04 | -$106.00K derived: sum of 3 quarters · filed 2016-02-16 | $60.00K derived: sum of 4 quarters · filed 2016-02-16 | |
| 2014-03-31 | -$27.00K 10-Q · filed 2015-05-04 | -$188.00K derived: sum of 2 quarters · filed 2016-02-16 | -$22.00K derived: sum of 3 quarters · filed 2016-02-16 | -$192.00K derived: sum of 4 quarters · filed 2016-02-16 | |
| 2013-12-31 | -$161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $5.00K derived: sum of 2 quarters · filed 2016-02-16 | -$165.00K derived: sum of 3 quarters · filed 2016-02-16 | -$154.00K 10-K · filed 2016-02-16 | |
| 2013-09-30 | $166.00K 10-Q · filed 2014-11-06 | -$4.00K derived: sum of 2 quarters · filed 2014-11-06 | $7.00K 10-Q · filed 2014-11-06 | -$12.00K derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-06-30 | -$170.00K 10-Q · filed 2014-07-31 | -$159.00K 10-Q · filed 2014-07-31 | -$178.00K derived: sum of 3 quarters · filed 2015-02-13 | -$109.00K derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-03-31 | $11.00K 10-Q · filed 2014-05-05 | -$8.00K derived: sum of 2 quarters · filed 2015-02-13 | $61.00K derived: sum of 3 quarters · filed 2015-02-13 | $166.00K derived: sum of 4 quarters · filed 2015-02-13 | |
| 2012-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $50.00K derived: sum of 2 quarters · filed 2015-02-13 | $155.00K derived: sum of 3 quarters · filed 2015-02-13 | $305.00K 10-K · filed 2015-02-13 | |
| 2012-09-30 | $69.00K 10-Q · filed 2013-11-07 | $174.00K derived: sum of 2 quarters · filed 2013-11-07 | $324.00K 10-Q · filed 2013-11-07 | $247.00K derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-06-30 | $105.00K 10-Q · filed 2013-08-02 | $255.00K 10-Q · filed 2013-08-02 | $178.00K derived: sum of 3 quarters · filed 2014-02-11 | $135.00K derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-03-31 | $150.00K 10-Q · filed 2013-05-08 | $73.00K derived: sum of 2 quarters · filed 2014-02-11 | $30.00K derived: sum of 3 quarters · filed 2014-02-11 | $31.00K derived: sum of 4 quarters · filed 2014-02-11 | |
| 2011-12-31 | -$77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$120.00K derived: sum of 2 quarters · filed 2014-02-11 | -$119.00K derived: sum of 3 quarters · filed 2014-02-11 | -$119.00K 10-K · filed 2014-02-11 | |
| 2011-09-30 | -$43.00K 10-Q · filed 2011-11-03 | -$42.00K derived: sum of 2 quarters · filed 2012-08-08 | -$42.00K 10-Q · filed 2012-11-06 | -$43.00K derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-06-30 | $1.00K 10-Q · filed 2012-08-08 | -$68.00K 10-Q · filed 2011-08-09 | $1.00K 10-Q · filed 2012-08-08 | $0.00 derived: sum of 3 quarters · filed 2013-03-01 | -$52.00K derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $69.00K 10-Q · filed 2012-05-10 | -$1.00K derived: sum of 2 quarters · filed 2013-03-01 | -$53.00K derived: sum of 3 quarters · filed 2013-03-01 | -$13.00K derived: sum of 4 quarters · filed 2013-03-01 | |
| 2010-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$122.00K derived: sum of 2 quarters · filed 2013-03-01 | -$82.00K derived: sum of 3 quarters · filed 2013-03-01 | $46.00K 10-K · filed 2013-03-01 | |
| 2010-09-30 | -$52.00K 10-Q · filed 2011-11-03 | -$12.00K derived: sum of 2 quarters · filed 2011-11-03 | $116.00K 10-Q · filed 2011-11-03 | -$20.00K derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-06-30 | $40.00K 10-Q · filed 2011-08-09 | $168.00K 10-Q · filed 2011-08-09 | $32.00K derived: sum of 3 quarters · filed 2012-02-22 | -$174.00K derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-03-31 | $128.00K 10-Q · filed 2011-05-06 | -$8.00K derived: sum of 2 quarters · filed 2012-02-22 | -$214.00K derived: sum of 3 quarters · filed 2012-02-22 | -$1.06M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2009-12-31 | -$136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$342.00K derived: sum of 2 quarters · filed 2012-02-22 | -$1.19M derived: sum of 3 quarters · filed 2012-02-22 | -$3.18M 10-K · filed 2012-02-22 | |
| 2009-09-30 | -$206.00K 10-Q · filed 2010-10-28 | -$1.05M derived: sum of 2 quarters · filed 2010-10-28 | -$3.04M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | -$843.00K 10-Q · filed 2010-08-03 | -$2.84M 10-Q · filed 2010-08-03 | |||
| 2008-12-31 | $3.68M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |